Whalesbook
NGL Fine-Chem Reports Strong Q4 and FY26 Results
NGL Fine-Chem's revenue from operations surged 57% to ₹149.23 crore in Q4 FY26 compared to ₹94.97 crore in Q4 FY25. For the full fiscal year FY26, revenue grew 36% to ₹500.95 crore from ₹368.26 crore in FY25. Profit after tax (PAT) for FY26 reached ₹48.13 crore, a significant increase from ₹21.12 crore in the previous fiscal year. In the fourth quarter, PAT jumped from ₹0.54 crore to ₹13.49 crore.
Reader Takeaway: Strong revenue growth driven by capacity expansion, but watch for Phase II delays and margin pressures.
What just happened
NGL Fine-Chem announced its financial results for the fourth quarter and full fiscal year ending March 31, 2026. The company reported robust year-on-year growth in both revenue and profit for the period.
Why this matters
The strong performance indicates NGL Fine-Chem's ability to scale operations and improve profitability. The ongoing capacity expansion is crucial for future growth, and the results show its positive impact.
The backstory
NGL Fine-Chem is a manufacturer of active pharmaceutical ingredients (APIs) and intermediates. The company has been focused on expanding its manufacturing capabilities to meet growing demand.
What changes now
Phase I of the capacity expansion is contributing to volume growth. The company is awaiting commissioning of Phase II, expected in early Q2 FY27, which is projected to add ₹350-400 crore in turnover over 3-4 years. Management has guided for EBITDA margins of 15% to 18%.
Risks to watch
Phase II commissioning has seen a delay and is now slated for early Q2 FY27. The timeline for a USFDA audit remains uncertain, which is critical for entering regulated US markets. High competition from China and India continues to pose a risk to margins.
Peer comparison
NGL Fine-Chem operates in the competitive API and intermediates market, facing pressure from both domestic and international players, particularly from China. Its focus on specific therapeutic areas and capacity expansion aims to differentiate its market position.
Context metrics (time-bound)
- Q4 FY26 Revenue: ₹149.23 crore (up 57% YoY)
- FY26 Revenue: ₹500.95 crore (up 36% YoY)
- FY26 PAT: ₹48.13 crore (up 128% YoY)
- Q4 FY26 EBITDA Margin: 14.35%
- FY26 EBITDA Margin: 14.51%
- Capex Invested: ₹182.75 crore (out of ₹210 crore planned)
What to track next
Investors will closely monitor the commissioning of Phase II capacity and its ramp-up. The outcome of any USFDA audit and its impact on market access, along with the company's ability to maintain its target EBITDA margins amidst cost pressures, will be key.